Overview
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing and delivering therapies for serious, complex diseases. Its core areas include neurology, specialized immunology and rare diseases; its portfolio includes multiple sclerosis medicines and therapies for spinal muscular atrophy, Alzheimer’s disease, ALS and other conditions.[1][2]
The company’s stated purpose is to develop innovative therapies for people living with serious and complex diseases. Biogen operates internationally, with approximately 7,500 employees worldwide as of December 31, 2025, including about 3,300 outside the United States.[1][3]
For the year ended December 31, 2025, Biogen reported total revenue of approximately $9.9 billion.[4] [1][2][3][4]
Products & services
Biogen’s product portfolio includes treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), Friedreich’s ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and postpartum depression, as well as biosimilars. Its MS products are VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY; SPINRAZA treats SMA; SKYCLARYS treats Friedreich’s ataxia; and QALSODY is a treatment for adults with ALS associated with a SOD1 mutation. LEQEMBI (lecanemab), an anti-amyloid antibody for Alzheimer’s disease, is commercialized with Eisai; ZURZUVAE for postpartum depression is commercialized with Supernus. Biogen’s biosimilars include BENEPALI (etanercept), IMRALDI (adalimumab) and FLIXABI (infliximab).[2][1][5][6][7]
In the quarter ended June 30, 2026, Biogen reported $1.916 billion in net product revenue. By reported product category, MS contributed $963.3 million (50.2%), rare disease $601.7 million (31.4%), biosimilars $152.8 million (8.0%), specialized immunology $127.8 million (6.7%) and other $70.8 million (3.7%). Product-level revenues included $450.8 million for TYSABRI, $401.9 million for SPINRAZA, $196.5 million for VUMERITY and $167.9 million for SKYCLARYS. The company also reports revenue from collaborations—including LEQEMBI-related revenue—and contract manufacturing, royalties and other activities separately from product revenue.[8][9][10] [2][1][5][6][8][9][7][10]
Geographic presence
In the first half of 2026, Biogen reported product revenue of $1.954 billion in the U.S. and $1.715 billion in the rest of the world; these represented 37.5% and 32.9% of total revenue, respectively. Its 2025 product revenue by reported geography was $3.548 billion in the U.S. (49.8%), $1.872 billion in Europe (26.3%), $853 million in Germany (12.0%), $419 million in Asia (5.9%) and $428 million in other markets (6.0%). The filing lists Germany separately from Europe, and does not provide a country-level breakdown for the rest of the world in the 2026 interim figures.[11][12]
Biogen’s principal executive offices are in Cambridge, Massachusetts. Its geographic footprint also includes a large-scale biologics manufacturing facility in Solothurn, Switzerland, and U.S. facilities in Research Triangle Park, North Carolina; the company identifies Cambridge and South San Francisco, California, as locations of its U.S. research and development teams.[13][14][15][16] [11][11][12][12][12][12][12][13][14][15][16][16]
Business segments
Biogen reports one operating segment, managed as a whole rather than as separate business segments. Its product-revenue categories are therefore portfolio groupings, not reportable segments.[17][18]
For FY2025, product revenue was $7.12 billion. Multiple sclerosis products—including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI—contributed $4.04 billion, approximately 56.7% of product revenue. Rare-disease products, including SPINRAZA, QALSODY and SKYCLARYS, contributed $2.15 billion (30.3%); biosimilars contributed $729 million (10.2%); and the “Other” products category contributed $197 million (2.8%). Percentages are calculated from the reported product-revenue total.[19][20][21][22][23][24]
Biogen also reports revenue streams outside those product categories: anti-CD20 therapeutic programs generated $1.86 billion, and its Alzheimer’s collaboration generated $178 million. These are separate revenue lines, not additional operating segments.[25][4] [17][19][19][19][19][19][20][21][22][23][24][25][4][18]
Company history
Biogen was founded in Geneva in 1978 by scientists Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Sharp. In 1979, its researchers announced the synthesis of hepatitis B virus protein antigens in bacteria, an early milestone in biotechnology.[26][27] Biogen launched AVONEX in the United States in 1996 and Europe in 1997, and later expanded its multiple-sclerosis portfolio with TYSABRI, approved in 2004, and TECFIDERA, approved in 2013.[28][29][30]
In 2003, Biogen merged with IDEC Pharmaceuticals to form Biogen Idec.[31] Biogen separated its hemophilia business in 2017, creating Bioverativ.[32] In 2021, the FDA granted accelerated approval to ADUHELM for Alzheimer’s disease.[33] In 2023, Biogen completed its acquisition of Reata Pharmaceuticals, whose medicine Skyclarys had been approved for Friedreich’s ataxia; that year, LEQEMBI, developed with Eisai, received traditional FDA approval.[34][35] [35][26][27][28][29][30][31][32][33][34]
Sources
- BIOGEN INC. — Full financial report (2025 Y)
- www.biogen.com[7]
- BIOGEN INC. — Full financial report (2026 Q 2)
- BIOGEN INC. — Press release (2026 Q 2)[9]
- www.sec.gov[10]
- www.biogen.com[16]
- www.sec.gov[18]
- www.biogen.com[26]
- investors.biogen.com[27]
- investors.biogen.com[28]
- investors.biogen.com[29]
- www.accessdata.fda.gov[30]
- www.sec.gov[31]
- investors.biogen.com[32]
- investors.biogen.com[33]
- investors.biogen.com[34]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore BIOGEN INC. in Finbar ↗